Oncology

@onc_ce on Twitter

Harold J Burstein MD PhD

Dr. Burstein is a medical oncologist at Dana-Farber Cancer Institute, and professor of medicine at Harvard Medical School.

He studied at Harvard College, earned an MD-PhD at HMS, and trained at Mass. General in internal medicine before coming to DFCI. A clinical investigator and scholar, he is a leading contributor to breast cancer guidelines from ASCO, the NCCN, and the St Gallen International Consensus panels, and has served on the US FDA Oncology Drug Advisory Committee. His writings can be found in the leading journals such as the New England Journal of Medicine, the Journal of Clinical Oncology, and other medical and online media.
Read More
Dr. Aakash Desai
MBBS, MPH is hematology and medical oncology fellow at MayoClinic, Rochester
His research focuses on evidence base in oncology, clinical trials, drug development, cancer care quality, healthcare delivery and global oncology. Dr. Desai received his medical degree from the prestigious B.J Medical College in Ahmedabad, India. He holds a master’s degree in public health from the University of Texas Health Science Center in Houston.
Following this Dr. Desai completed his residency at the University of Connecticut. At the University of Connecticut, he also completed certification in Health Professions Education from University of Connecticut. Subsequently in 2020 he joined the fellowship program in oncology and hematology at the Mayo Clinic. Dr. Desai received the 2021 Conquer Cancer Foundation ASCO Young Investigator Award and 2021 International Association for the Study of Lung Cancer Early Career Award. He has also received the Education award at the Targeted Therapies in Lung Cancer Conference 2022 (TTLC22), and the International Cancer Foundation scholarship for the ESMO Targeted Anticancer Therapies (TAT) 2022. Dr. Desai continues to focus on clinical and patient-oriented research in thoracic malignancies with a keen interest in drug development and clinical trials.
Read More
Beth Faiman PhD, MSN, SPRN-BC, AOCN, FAAN
Dr. Faiman has become an exemplary leader in bringing critical knowledge in cancer nursing to clinical providers- locally, nationally and internationally.
She demonstrates enthusiasm for continuous learning by conducting innovative research, and has demonstrated the importance of using and integrating new medical knowledge within nursing practices. As an advanced practice nurse at the Cleveland Clinic, she led institutional quality initiatives to lessen chemotherapy wait times for cancer patients. A founding member of the International Myeloma Foundation Nurse Leadership Board since 2006, she also successfully lobbied to enhance nurse prescribing privileges that year. In 2014 she co-developed nurse-led consult clinics to expedite diagnosis and management of thrombosis in cancer patients, and plasma cell disorders. Faiman is a clinical member of the Case Comprehensive Cancer Center (Case CCC) under the Cancer Prevention, Control and Population (CPC) Research Program. Dr. Faiman has established herself as an internationally renowned nurse expert in cancer nursing through her research, publications, and presentations; and more importantly, she has been an initiator of educational forums that bring new knowledge to underserved areas. In 2019 she was acknowledged as a distinguished Fellow of the American Academy of Nursing (FAAN), appointed to the American Board of Internal Medicine Hematology Specialty Board, and in 2020 appointed as Editor-in-Chief, Journal of Advanced Practitioner in Oncology, the official journal of Advanced Practitioner Society for Hematology and Oncology (APSHO). Dr. Faiman demonstrates energy for advancing cancer care and immerses herself in national and international programs, services and leadership work within myeloma communities.
Read More
Erika P. Hamilton, M.D.
Director, Breast and Gynecologic Cancer Program Sarah Cannon Research Institute/Tennessee Oncology

Dr. Hamilton received her undergraduate degree from Washington and Lee University in Virginia and received a NCAA Postgraduate Scholarship.

She then completed her medical degree and residency from University of North Carolina in Chapel Hill and fellowship training in oncology at Duke University. She joined Sarah Cannon Research Institute as investigator in drug development for women’s cancers in 2013. In 2015 she became the Director of the Breast and Gynecologic Cancer Research Program. She sees patients facing breast and gynecologic cancers from standard of care to phase II/III to phase I drug development. Dr. Hamilton is the past Chair of ASCO’s Scientific Committee for Metastatic Breast Cancer for 2019-2020. She serves on the Board of Directors for Susan G Komen middle Tennessee for 3 years running and is an Associate Editor for Clinical Breast Cancer. She was named to the Women to Watch Class of 2021 for Nashville Medical News. She is also in ASCO’s current Leadership Development Class for 2021-2022.
Read More
Suneel Kamath, MD

Suneel Kamath, MD is an Assistant Professor of Medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University and a gastrointestinal oncologist at Cleveland Clinic Taussig Cancer Institute in Cleveland, Ohio.

His research program focuses on novel drug development in gastrointestinal cancers, health disparities and strategies to understand and prevent young-onset gastrointestinal cancers. Dr. Kamath received his medical degree from Columbia University College of Physicians & Surgeons. His post-doctoral training included residency in internal medicine and fellowship in hematology/oncology at Northwestern University Feinberg School of Medicine. During his time there, he was awarded the Nora Cooney Marra Compassionate Care Award from The Woman’s Board of Northwestern Memorial Hospital. Dr. Kamath is an active member of Cleveland Clinic’s Center for Young-Onset Colorectal Cancer (yoCRC) and has advised the United States Congress on health policy related to yoCRC. He is a member of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel’s (CPGC) Multisite Guidelines Advisory Group and a member of the ASCO Professional Development Committee.
Read More
Dr. Pashtoon Kasi, MD, MS
Dr. Pashtoon Kasi, MD, MS is an oncologist and researcher at Weill Cornell Medicine and NewYork-Presbyterian Hospital. He focuses on treating patients with gastrointestinal (GI) cancers and the treatment of patients with novel drugs/early-phase clinical trials. At Weill Cornell Medicine, Dr. Kasi additionally serves as the Director for Colorectal Cancer Research, as well as Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine.
Dr. Kasi received his medical degree from the prestigious Aga Khan University (AKU) in Pakistan in 2006. He did a year of internship at the University of Texas Health Science Center at San Antonio (UTHSCSA) in 2009. Following this Dr. Kasi completed his residency at the International Scholars Program (ISP) at the University of Pittsburgh Medical Center (UPMC). Subsequently in 2016 he completed a fellowship in oncology and hematology at the Mayo Clinic. At the Mayo Clinic, he also completed a post-doctoral master’s program at the Mayo School of Graduate Medical Education (MSGME) in clinical and translational sciences (Masters in Basic Sciences). Prior to joining Weill Cornell Medicine, Dr. Kasi served as an Associate Professor of Medicine at the Division of Hematology and Oncology at the University of Iowa. Before that, he was an Assistant Professor of Medicine and Oncology at both University of Iowa and Mayo Clinic. Dr. Kasi was one of a select few who were appointed to the academic post of Assistant Professor of Oncology and Assistant Professor of Medicine at the Mayo Clinic during his fellowship due to his research and academic achievements. Dr. Kasi’s research focus has been on “liquid biopsies” [(circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs)], alongside developing and conducting clinical trials focused on precision oncology and precision medicine. Dr. Kasi is an author and editor of several books including: “Research: What, Why and How: A Treatise from Researchers to Researchers”, and “Impact of circulating tumor DNA (ctDNA) in Patients with Gastrointestinal Malignancies” and has over 100 publications in leading peer-reviewed journals. Additionally, Dr. Kasi has been active as a principal investigator on numerous investigator-initiated, industry-sponsored as well as cooperative group clinical trials in oncology.
Read More
Alok A. Khorana, M.D., F.A.C.P, F.A.S.C.O

Alok A. Khorana, M.D., F.A.C.P, F.A.S.C.O, is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Academic Development of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio.

Alok A. Khorana, M.D., F.A.C.P, F.A.S.C.O, is Professor of Medicine, Cleveland Clinic Lerner College of Medicine, Case Western Reserve University, the Sondra and Stephen Hardis Chair in Oncology Research, Vice-Chair for Academic Development of the Taussig Cancer Institute (part of Case Comprehensive Cancer Center) and Director of the Gastrointestinal Malignancies Program at the Cleveland Clinic, Cleveland, Ohio. His clinical and translational research program focuses on predictive factors and drug development in cancer-associated thrombosis and gastrointestinal cancers and has been funded by grants from the National Cancer Institute, the National Heart, Lung, and Blood Institute, the Hardis Family, the Porter Family Fund, VeloSano, the Cleveland Clinic Center for Excellence, the Scott Hamilton CARES Initiative, Stand Up To Cancer (Colorectal Cancer “Dream Team”) and the V Foundation. Dr. Khorana received his medical degree from Maharaja Sayajirao University’s Medical College in Baroda (now Vadodara, Gujarat), India. His postdoctoral training included a residency in internal medicine at the University at Buffalo in New York and a fellowship in hematology/oncology at the University of Rochester, New York. He is a Fellow of the American College of Physicians and in 2018 was elected Fellow of the American Society of Clinical Oncology. Dr. Khorana is Past Chair of the American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines Panel (CPGC), Chair of ASCO CPGC’s Pancreas Cancer Working Group, Co-Chair of ASCO CPGC’s Multisite Advisory Group and Co-Chair of the ASCO Guidelines Panel on Resectable Pancreas Cancer. He is currently Chair of the Medical and Scientific Advisory Board of the National Blood Clot Association. He was previously Chair of the ISTH Scientific Subcommittee on Hemostasis and Malignancy In 2019, Dr. Khorana was awarded the Cleveland Clinic’s Maria and Sam Miller Professional Excellence Award for Scientific Achievement in Clinical Research.
Read More
Dr. C. Ola Landgren
Professor of Medicine, Chief of Myeloma Program, Leader of Experimental Therapeutics Program at Sylvester Comprehensive Cancer Center at University of Miami (SCCC-UM)

Over the past several years, he designed and conducted a series of studies to define biological mechanisms of transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to multiple myeloma. Beyond traditional clinical criteria for complete remission, he developed strategies to define minimal residual disease (MRD) detection post-therapy in multiple myeloma using cell-, molecular-, and imaging-based methods. He has a strong track-record in drug development and served as a principal investigator for many clinical trials, with particular focus on early drug development and correlative science.

He leads the clinical and research operations along with the development of the Myeloma Program at SCCC-UM. He is a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. He is a member of several editorial boards and serves as a reviewer for grants and several high-impact journals. As a Program Member of the Cancer Center Support Grant, he participates in research activities as an independent investigator, a leader of research governance committees, and on multi-disciplinary research teams.
Read More
Dr. Suzanne Lentzsch

Dr. Lentzsch is a Professor of Medicine and the Director of the Multiple Myeloma and Amyloidosis Service at the Columbia University Medical Center, New York.

Her translational research focuses on identifying novel targets for the treatment of MM, MM bone disease, and AL amyloidosis. Dr. Lentzsch is a member of the NCI Myeloma Steering Committee, the ASH Scientific Committee for Plasma Cell Neoplasia, the ASCO Scientific Program Committee for Plasma cell dyscrasias, the Educational and Steering Committee for the Society of Hematology and Oncology (SOHO), and the SWOG Myeloma Working Group. She co-chairs the Career Development Committee of the International Myeloma Society (IMS). She is Associate Editor for JCO and on the Editorial Board for Blood Cancer Discoveries. Dr. Lentzsch’s translational research received grant support from the NCI, FDA, Pennsylvania Department of Health, Leukemia and Lymphoma Society, Multiple Myeloma Research Foundation, Cancer Research Institute, Emerson Collect Fund, and International Myeloma Society. Dr. Lentzsch has published over 120 original articles, editorials, chapters, many as the lead or senior author, in high-impact journals as JCI, JCO, Blood, Cancer Research, and Leukemia.
Read More
Ruben A. Mesa, MD, FACP

Executive Director

Mays Cancer Center at UT Health San Antonio MD Anderson

Mays Family Foundation Distinguished University Presidential Chair

Professor of Medicine

Dr. Ruben Mesa is the Executive Director of the NCI Designated Mays Cancer Center, at UT Health San Antonio MD Anderson Cancer Center. He is the Mays Family Foundation Distinguished University Presidential Chair and has spent his career focusing on myeloproliferative neoplasms. Dr. Mesa has been PI or Co-PI in over 100 clinical trials for MPNs, a co-lead on the NCI Funded MPN Research Consortium, and played key roles in the approval of ruxolitinib, fedratinib and ropegylated interferon alpha 2b. Dr. Mesa did his medical and specialty training at Mayo Clinic (MN) and was on the faculty and Cancer Center Leadership at Mayo Clinic from 2002-2017 (MN and AZ). Dr. Mesa was elected to the Board of Directors of the Leukemia and Lymphoma Society in 2018 and subsequently an officer of the board in 2020, and sits on the board of the MPN Education Foundation. Dr. Mesa has been an active member with AACI, AACR, ASH and ASCO with a variety of leadership roles and is currently an elected Board member for the American Association of Cancer Institute.
Read More
Martina Murphy, MD

Martina Murphy, MD is an associate professor of medicine in the Division of Hematology and Oncology at the University of Florida. She is clinical investigator and medical educator who specializes in caring for patients with gynecologic malignancies. Much of her research focuses on effective communication in the healthcare setting and the cultivation of equitable workplace and training environments. Dr. Murphy has a strong dedication to medical education and is actively involved on a national level in research in medical education primarily related to novel curriculum development, mentorship and career development. She serves as the Program Director for the Hematology/Oncology fellowship program and is a member of the UF Society of Teaching Scholars. Additionally, she directs the first year clinical skills course for pre-clerkship medical students at the UF College of Medicine.

Dr. Murphy is board certified in Internal Medicine, Hematology and Oncology and is a member of the American Society of Clinical Oncology (ASCO) and the American Society of Hematology (ASH) where she serves on the ASH Committee on Training and as a faculty mentor for the ASH Medical Educators Institute. She is also a participant in the ASCO Educational Scholars Program and serves on the ASCO Oncology Training Programs Committee as well as the ASCO Social Media Working Group.
Read More
Antonio Passaro MD, PhD
Medical Oncologist, Division of Thoracic Oncology, European Institute of Oncology, Milan, Italy

Antonio Passaro, MD, PhD is a medical oncologist at the Division of Thoracic Oncology of the European Institute of Oncology in Milan, Italy. He received the PhD in molecular medicine with a thesis on lung cancer.

He is a clinician and translational researcher specialized in lung cancer. His main areas or research and clinical interest are predictive biomarker, in particular EGFR, and related target and immunotherapy agents, from discovery to validation in clinical setting. He is also strongly involved and interested in using target agents in non-metastatic setting, alone or in multimodality approach for early or locally-advanced disease. Dr. Passaro is involved in a portfolio of many clinical trials, sponsored and academic, investigating new anticancer agents. He is currently a Member of the ESMO Council, Chair of the Press & Media Affairs Committee, and a member of ESMO Lung Cancer Faculty. He is also an AIOM (Italian Association of Medical Oncology) board member for lung cancer guidelines. Author of several peer-reviewed manuscripts, he serves on the Editorial Board of different clinical cancer journals, and acts as reviewer for multiple lung cancer publications.
Read More
Dr. Dale Shepard

Dale R. Shepard MD, PhD is the Director of the Taussig Phase I and Sarcoma programs at Cleveland Clinic. 

In this role, Dr. Shepard oversees the early development of the new cancer therapies including the genomic-based treatments and immunotherapies that are revolutionizing the care of patients with cancer. He sees nearly 200 sarcoma consults annually with patients from across the country. As a medical oncologist and clinical researcher, he has been the principal investigator for dozens of clinical trials and has been a recipient of a National Cancer Institute Cancer Clinical Investigator Team Leadership Award. Dr. Shepard is a thought leader for management of sarcoma, gastrointestinal and genitourinary cancers and has been a consultant for many pharmaceutical companies. Dr. Shepard earned a PhD in Pharmacology and his MD at The Ohio State University and completed a Clinical Pharmacology fellowship at the University of Chicago.
Read More
Dr. Ann Meredith Garcia Trinidad

Dr. Ann Meredith Garcia Trinidad is currently the Head of the Section of Medical Oncology of the Dagupan Doctors Villaflor Memorial Hospital (Philippines). She has a special interest in healthcare social media and medical writing, particularly as avenues for patient education and advocacy. She is an Advisory Panelist of the ASCO Cancer.Net Editorial Board and serves as one of the Instagram Editors of the OncoAlert Network.

Dr. Trinidad completed her medical degree (cum laude) from the University of the Philippines College of Medicine and proceeded with her Internal Medicine Residency Training and Medical Oncology Fellowship Training at the University of the Philippines- Philippine General Hospital, accompanied by a Master’s Degree in Clinical Medicine (Major in Medical Oncology). She is a Diplomate and Fellow of the Philippine Society of Medical Oncology (PSMO). In 2019, she was one of the graduates of the first ESMO Leaders Generation Programme (LGP) Asia and now serves as a member of the ESMO Membership Committee and the ESMO Practising Oncologists Working Group. In 2020, she also received an International Development and Education Award (IDEA) from the ASCO.
Read More